Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 8/20 | 0.52 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.52 |
| ▸ | LCK | P06239 | 2/20 | 0.52 |
| ▸ | FYN | P06241 | 2/20 | 0.52 |
| ▸ | CSF1R | P07333 | 2/20 | 0.52 |
| ▸ | RET | P07949 | 2/20 | 0.52 |
| ▸ | MET | P08581 | 2/20 | 0.52 |
| ▸ | ROS1 | P08922 | 2/20 | 0.52 |
| ▸ | FLT1 | P17948 | 2/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.52 |
| ▸ | STK3 | Q13188 | 2/20 | 0.52 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.52 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.52 |
| ▸ | PAK4 | O96013 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | BTK | Q06187 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3767846 | 0.90 | CDK19 (0.59) | IGF1RPRKD3MAP4K4LCKFYN | |
| SCHEMBL3767735 | 0.88 | CDK19 (0.47) | IGF1RCDK19ALKINSREGFR | |
| SCHEMBL3726694 | 0.86 | IGF1R (0.48) | IGF1RPRKD3MAP4K4LCKFYN | |
| SCHEMBL3762580 | 0.86 | CDK19 (0.62) | IGF1RPRKD3MAP4K4LCKFYN | |
| SCHEMBL3760802 | 0.84 | CDK2 (0.47) | IGF1RPRKD3MAP4K4LCKFYN | |
| SCHEMBL3756628 | 0.84 | IGF1R (0.48) | IGF1RPRKD3MAP4K4LCKFYN | |
| SCHEMBL3764610 | 0.84 | CDK19 (0.48) | IGF1RCDK19ALKINSREGFR | |
| SCHEMBL3767817 | 0.83 | IGF1R (0.56) | IGF1RPRKD3MAP4K4LCKFYN | |
| SCHEMBL3771416 | 0.83 | IGF1R (0.46) | IGF1RPRKD3MAP4K4LCKFYN | |
| SCHEMBL3725890 | 0.83 | CDK19 (0.64) | IGF1RPRKD3MAP4K4LCKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435436-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-07-30 | — | — | EP | claimed |
| US-8354422-B2 | Pyrimidine inhibitors of kinase activity | ABBOTT LABORATORIES INC. (US) | 2013-01-15 | — | — | US | claimed |
| WO-2010138576-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | claimed |
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | claimed |
| EP-2435436-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8354422-B2 | Pyrimidine inhibitors of kinase activity | ABBOTT LABORATORIES INC. (US) | 2013-01-15 | — | — | US | disclosed |
| WO-2010138576-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | IGF1R, CDK2, TK1 | IGF1R 1/4885PRKD3 186/4885MAP4K4 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.